Donor lymphocyte infusion has become established as a salvage therapy for patients with
hematological disorders relapsing after allogeneic bone marrow transplantation (BMT). The …

We investigated the use of 'prophylactic'donor lymphocyte infusions (DLI) containing 1× 10 7
CD3+ cells, given at 30, 60 and 90 days post-allogeneic blood and marrow transplantation …

Donor lymphocyte infusions can reinduce complete remission in the majority of patients with
chronic myelogenous leukemia (CML) who relapse into chronic phase after allogeneic bone …

Purpose We retrospectively evaluated the feasibility and safety of a modified prophylactic
donor lymphocytes infusion (DLI) approach in advanced leukemia. Materials and methods …

In this study, we tested the efficacy and safety of donor lymphocyte infusion (DLI) with
granulocyte colony-stimulating factor (G-CSF) priming in patients who relapsed after …

Donor lymphocyte infusions (DLI) are an effective treatment for patients with chronic myeloid
leukemia (CML) in relapse after allografting but the optimal cell dose has yet to be identified …

The goal of allogeneic (allo)-hematopoietic stem-cell transplantation (HSCT) in the treatment
of hematologic malignancies is to harness the graft-versus-leukemia (GVL) effect, while …

Donor leukocyte infusion (DLI) alone has very limited efficacy for patients with acute
lymphoblastic leukemia (ALL) who have relapsed after allogeneic bone marrow …

Donor leukocyte infusions after unrelated donor hematopoieti... : Current Opinion in
Oncology Donor leukocyte infusions after unrelated donor hematopoietic stem cell …

Donor lymphocyte infusions (DLI) were given between June 1990 and March 1996 to 18
patients with chronic myeloid leukemia (CML) for the treatment of cytogenetic (n= 6) or …